Asthma and Respiratory Disorders News

NASHVILLE, Tenn. — Intestinal fungal dysbiosis was associated with asthma severity, particularly hospital use in the previous year, with severity possibly exacerbated by crosstalk between the gut and the lung, according to study results.

Patients with poorly controlled asthma and mucus plugs had significantly more airflow obstruction, type 2 inflammation and severe exacerbations, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Higher prenatal C-reactive protein levels and increases in these levels from early to late pregnancy were associated with childhood asthma, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

NASHVILLE, Tenn. — There are no simple solutions in asthma treatment, as evidenced by a debate that covered airway remodeling and the use of oscillometry among other topics at the CHEST Annual Meeting.

Epstein-Barr virus replication may be a cofactor in a subgroup of patients who develop long COVID fatigue, although other potential contributing factors need to be evaluated as well, according to a letter published in Allergy.

Daily inhaled corticosteroid and bronchodilator therapy may help children with reversible peripheral airway obstruction and lung hyperinflation after developing persistent dyspnea despite normal spirometry, according to a recent case study.

The use of acid suppressants among children may increase their risks for incident asthma, atopic dermatitis and allergic rhinitis, according to a systematic review published in The Journal of Allergy and Clinical Immunology: In Practice.

NASHVILLE, Tenn. — Experts found both consensus and contention during a roundtable discussion of the use of biologics to treat severe asthma, modelled on the ESPN program “Pardon the Interruption,” during the CHEST Annual Meeting.

NASHVILLE, Tenn. — Patients with asthma who experience anaphylaxis have higher rates of complications, 30-day readmissions and mortality than those without anaphylaxis, according to a presentation at the CHEST Annual Meeting.

NASHVILLE, Tenn. — Children aged 6 to 11 years with uncontrolled, moderate to severe type 2 asthma experienced clinical improvements with dupilumab through a 2-year study period, according to a presentation at the CHEST Annual Meeting.